Changes in smoking habit among patients with a history of oral squamous cell carcinoma (OSCC)

Abstract

Objective: To determine the changes in smoking habit among patients with oral squamous cell carcinoma (OSCC) diagnosed and treated in the Service of Stomatology (Valencia University General Hospital. Valencia, Spain). Material and methods: The study involved 123 patients with a history of OSCC interviewed by telephone on their smoking habits at the time of the diagnosis and modifications in habits subsequently. The mean age at diagnosis was 60 years and 9 months (standard deviation, SD ± 12 years and 2 months). Males predominated (61.8%) over females (38.2%). The mean time from the diagnosis of OSCC to the survey was 4 years and 6 months (SD ± 3 years and 6 months). Results: Almost one-half of the patients (45.5%) were active smokers at the time of the diagnosis, with a mean duration of the habit of 34.9 years (SD ± 12 years and 7 months). In turn, 19.5% of the patients were ex-smokers at diagnosis, with an average of 13 years and 9 months (SD ± 9 years and 4 months) from smoking cessation to the development of cancer. A total of 57.1% of the smokers abandoned the habit at diagnosis, 8.9% continued to smoke to the same extent as before, and 33.9% reduced smoking. Conclusion: A full 44.4 % of our patients diagnosed with OSCC continued to smoke despite warnings of the risks, and although the majority claimed to have reduced their smoking habit, interventional strategies would be indicated to help ensure complete smoking cessation.

Feasibility and Efficacy of an Addiction Treatment Program in Patients With Upper Aerodigestive Tract Cancer

“…These abstinence rates for tobacco and alcohol were similar to those previously reported (Allison, 2001;Poveda-Roda, Bagán, Jiménez-Soriano, Margaix-Muñoz, & Sarrión-Pérez, 2010), but in the literature, we found no figures concerning double withdrawal of alcohol and tobacco. These spontaneous cessations could be the consequence of advice given by the medical team or nursing staff, as reported by Cooley et al (2011), because no information meeting and no visit to an addiction treatment center had been systematically organized during the period of the cancer treatment.…”

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

“…In 27.5% ( n =36) of studies, there was sufficient information to determine the prevalence of current smoking among participants who were current smokers at cancer diagnosis (4, 5, 34-36, 39, 40, 44, 46, 56, 60, 65, 76, 80-84, 87, 97, 110, 112, 115, 117, 123, 125, 128, 129, 136-138, 142-144, 149, 153). In many cases, the definition used to classify current smokers at cancer diagnosis was unreported (38.9% ( n =14/36) (e.g., (4, 31, 87, 110, 128))).…”

“…Ns denote number of studies in the analysis for Full Sample/Current Smokers at Cancer Diagnosis. Full Sample: 0-3 includes data from (4, 10, 34, 40, 42, 54, 63, 73, 80, 84, 110, 127, 132, 134, 135, 143, 145, 147, 154); 4-6 includes data from (51, 131, 153); 7-11 includes data from (49, 133); 12-59 includes data from (59, 79, 85, 86, 88, 91, 97, 100, 141, 152); 60+ includes data from (67, 70, 128); and Mixed includes data from (5, 29-31, 46, 52, 56, 62, 69, 90, 94, 95, 98, 103, 112, 115, 120-122, 125, 126, 130, 138). Current Smokers at Cancer Diagnosis: 0-3 includes data from (4, 34, 39, 40, 80, 82, 84, 110, 143, 149); 4-6 includes data from (76, 153); 7-11 includes data from (123); 12-59 includes data from (36, 97); 60+ includes data from (128); and Mixed includes data from (5, 35, 44, 46, 56, 112, 115, 125, 129, 138).…”

“…Full Sample: Before Treatment includes data from (4, 10, 28, 32, 43, 45, 57, 59, 63-65, 68, 73, 74, 84, 99, 101, 102, 106, 108, 109, 111, 114, 127, 132, 134, 143, 148, 151, 154); During Treatment includes data from (34, 40, 75, 104, 110, 118, 121, 133, 145-147, 152) (33, 37, 38, 50, 78, 107, 124, 139, 150); After Treatment includes data from (29, 30, 49, 53, 58-60, 67, 69, 70, 79, 85-87, 89, 92, 97, 98, 100, 103, 105, 119, 122, 128, 138, 141); and Mixed includes data from (5, 41, 42, 46, 47, 52, 55, 61, 62, 73, 77, 80, 83, 90, 91, 93, 94, 96, 115, 126, 130, …”

Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer

“…[2–7] DMEs are relevant in cancer survival due to their role in metabolism of cancer chemotherapies[8] and commonly encountered dietary and environmental carcinogens. [9, 10] In addition, 20–40% of OOSCC patients continue smoking after diagnosis,[11–14] implying tobacco-metabolic DMEs may affect survival in a substantial proportion of OOSCC patients. The study of DMEs and OOSCC survival is of particular interest considering advances in OOSCC treatment have not substantially impacted survival.…”